Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222955 | 1.00 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL18358031 | 1.00 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL77858 | 0.98 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL65491 | 0.98 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL65490 | 0.98 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL6219872 | 0.93 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67044 | 0.93 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL85536 | 0.93 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67045 | 0.93 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL27877016 | 0.93 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250034166-A1 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20240383922-A1 | KRAS Modulating Compounds | GILEAD SCIENCES, INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2024216094-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024215754-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024178304-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-1327766-C | Compounds, compositions, and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1307875-C | Compounds, compositions and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2007-04-04 | — | — | CN | disclosed |
| US-20060165648-A1 | Compounds, compositions, and methods for controlling biofilms | DEGENHARDT CHARLES R | 2006-07-27 | — | — | US | disclosed |
| US-7018642-B2 | Compounds, compositions, and methods for controlling biofilms | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1699545-A | Apparatus and method for controlling biofilms | PROCTER & GAMBLE (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1689405-A | Compounds, compositions, and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2005-11-02 | — | — | CN | disclosed |
| CN-1527876-A | Compounds, compositions and methods for controlling biofilms | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1381668-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | THE PROCTER & GAMBLE COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030105072-A1 | Compounds, compositions, and methods for controlling biofilms | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2002088298-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383922-A1 | KRAS Modulating Compounds | KRAS, NRAS, HRAS | HSD17B10 4557/4885SMN1; SMN2 3325/4885RAB9A 77/4885 |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | HSD17B10 1764/4885SMN1; SMN2 4688/4885RAB9A 2300/4885 |
| US-20250034166-A1 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | KRAS, NRAS, HRAS | HSD17B10 3868/4885SMN1; SMN2 4125/4885RAB9A 70/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | HSD17B10 1168/4885SMN1; SMN2 881/4885RAB9A 2345/4885 |
| US-20060165648-A1 | Compounds, compositions, and methods for controlling biofilms | BMP2, BMP1, BMP4 | HSD17B10 3332/4885SMN1; SMN2 4869/4885RAB9A 2871/4885 |
| US-20030105072-A1 | Compounds, compositions, and methods for controlling biofilms | BMP2, BMP1, BMP4 | HSD17B10 3332/4885SMN1; SMN2 4869/4885RAB9A 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.